New cancer drug DCR-PDL1 enters first human safety tests
NCT ID NCT06504368
First seen Nov 06, 2025 · Last updated May 23, 2026 · Updated 22 times
Summary
This early-stage study is testing a new drug called DCR-PDL1 in about 32 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose by giving it through an IV in increasing amounts. Researchers will closely monitor side effects and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NEXT Oncology
RECRUITINGIrving, Texas, 75039, United States
-
Next Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.